sellWeak cluster of 210b5-1 plan
Thomas Sandgaard sold $51k of ZYXI
PRESIDENT, CEO AND CHAIRMAN at ZYNEX INC. 6,000 shares at an average of $8.51, traded Nov 4, 2024, filed Nov 6, 2024.
Warning score
20Value
$51k
6,000 shares
Holdings after
14,615,662
-0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +7Trade size$51k at market
- 0Share of holdings soldSold 0.0% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-026282, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 4, 2024 | SOpen-market sale Common Stock10b5-1 | -2,000 | $8.67 | $17k | 14,619,350 | Nov 6, 2024 |
| Nov 5, 2024 | SOpen-market sale Common Stock10b5-1 | -2,000 | $8.05 | $16k | 14,617,662 | Nov 6, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stock10b5-1 | -2,000 | $8.82 | $18k | 14,615,662 | Nov 6, 2024 |
Related signals
Other insiders at ZYNEX INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 16Weak | ZYNEX INC | Daniel J Moorhead CHIEF FINANCIAL OFFICER | $81k 10,000 shares | -22% | |
| 13Weak | ZYNEX INC | Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN | $16k 2,000 shares | -0% | |
| 22Weak | ZYNEX INC | Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN | $89k 10,000 shares | -0% | |
| 24Weak | ZYNEX INC | Daniel J Moorhead CHIEF FINANCIAL OFFICER | $86k 10,000 shares | -18% | |
| 20Weak | ZYNEX INC | Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN | $53k 6,000 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.